PFE Stock Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Pfizer Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.28 |
| 52 Week High | US$31.54 |
| 52 Week Low | US$20.92 |
| Beta | 0.50 |
| 1 Month Change | -0.93% |
| 3 Month Change | -13.44% |
| 1 Year Change | -20.46% |
| 3 Year Change | -55.37% |
| 5 Year Change | -41.00% |
| Change since IPO | 4,816.98% |
Recent News & Updates
Recent updates
Pfizer's Q1 Update May Mark A Bottom In The Stock
Apr 30Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle
Apr 23It Looks Like Pfizer Inc.'s (NYSE:PFE) CEO May Expect Their Salary To Be Put Under The Microscope
Apr 17
Pfizer: Tasty 7% Yield
Apr 16
R&D And Savings Programs Will Strengthen Future Outlook
Apr 08 Focus on R&D productivity in 2025 may risk misalignment with market needs, impacting future revenue if new products underperform.Oncology Integration And Phase III Trials Will Redefine Future
Apr 07 Pfizer's oncology focus strengthens its portfolio and future revenue through Seagen integration and promising R&D pipeline developments in oncology and vaccines.Pfizer: Shares Stabilize At $25 As Institutions Begin To Load Up (Rating Upgrade)
Mar 28Pfizer: Bulls Need To Check Out Its Graham P/E
Mar 22Pfizer's Future Depends on Oncology Growth, New Products and operational efficiency
Mar 20I think that Pfizer has a strong pipeline. The aquisition of seagen added many new oncology products that will continue to grow by 14% partially offseting the decline on sales of the covid-19 vaccinesPfizer: Undervalued Safe Haven In Risk-Off Market
Mar 11Pfizer Remains A Good Pick For Dividend Investors
Mar 04Market Still Lacking Some Conviction On Pfizer Inc. (NYSE:PFE)
Feb 28Why Pfizer's Stock Price Isn't Reflecting Its True Value
Feb 19Pfizer: 3 Key Risks That Warrant A Sell
Feb 12Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
Feb 04These 4 Measures Indicate That Pfizer (NYSE:PFE) Is Using Debt Extensively
Feb 04Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Jan 28Pfizer's (NYSE:PFE) Upcoming Dividend Will Be Larger Than Last Year's
Jan 13Pfizer: My Top Play In 2025 Using Dogs Of The Dow Strategy
Jan 13Pfizer: One Of The Next Big AI Winners
Dec 30Pfizer (NYSE:PFE) Is Paying Out A Larger Dividend Than Last Year
Dec 30Pfizer: Time And Patience Ran Out (Rating Downgrade)
Dec 24Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call
Dec 18Pfizer's (NYSE:PFE) Dividend Will Be Increased To $0.43
Dec 16Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns
Dec 11Pfizer: Too Cheap To Ignore
Dec 05Shareholder Returns
| PFE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -7.9% | -6.9% | -0.3% |
| 1Y | -20.5% | -10.0% | 8.0% |
Return vs Industry: PFE underperformed the US Pharmaceuticals industry which returned -10% over the past year.
Return vs Market: PFE underperformed the US Market which returned 8% over the past year.
Price Volatility
| PFE volatility | |
|---|---|
| PFE Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 11.0% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: PFE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PFE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1849 | 81,000 | Albert Bourla | www.pfizer.com |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands.
Pfizer Inc. Fundamentals Summary
| PFE fundamental statistics | |
|---|---|
| Market cap | US$130.59b |
| Earnings (TTM) | US$7.87b |
| Revenue (TTM) | US$62.46b |
16.1x
P/E Ratio2.0x
P/S RatioIs PFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PFE income statement (TTM) | |
|---|---|
| Revenue | US$62.46b |
| Cost of Revenue | US$15.98b |
| Gross Profit | US$46.49b |
| Other Expenses | US$38.62b |
| Earnings | US$7.87b |
Last Reported Earnings
Mar 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.38 |
| Gross Margin | 74.42% |
| Net Profit Margin | 12.59% |
| Debt/Equity Ratio | 68.8% |
How did PFE perform over the long term?
See historical performance and comparisonDividends
7.7%
Current Dividend Yield122%
Payout RatioDoes PFE pay a reliable dividends?
See PFE dividend history and benchmarks| Pfizer dividend dates | |
|---|---|
| Ex Dividend Date | May 09 2025 |
| Dividend Pay Date | Jun 13 2025 |
| Days until Ex dividend | 2 days |
| Days until Dividend pay date | 33 days |
Does PFE pay a reliable dividends?
See PFE dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/09 22:25 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pfizer Inc. is covered by 52 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Kerry Holford | Berenberg |
| Luisa Hector | Berenberg |